๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Trials with a site in Shenzhen

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
NCT07504445Advanced Solid Tumors
Peking University Shenzhen Hospital
Phase EARLY_PHASE1
10
Shenzhen
2026-06-10
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
NCT07101549Advanced Solid Tumors
changjianhua
Phase 1
25
Shenzhen
2025-08-01
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
NCT05944224Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xiโ€™an
2023-10-17
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies with a site in Shenzhen that also match the filters currently applied.

How many clinical trials are recruiting in Shenzhen?

3 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shenzhen), 6 studies
PhaseStudiesRecruitingShare
Phase 13150%
Phase 1/22233.3%
Phase EARLY_PHASE11016.7%

Most active sponsors

Lead sponsors with the most studies (Shenzhen)
Lead sponsorStudiesRecruiting
Bayer10
Beijing Biotech11
Bristol-Myers Squibb11
changjianhua10
Peking University Shenzhen Hospital10
Shanghai Pharmaceuticals Holding Co., Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.